146 related articles for article (PubMed ID: 17306926)
1. Mortalin sensitizes human cancer cells to MKT-077-induced senescence.
Deocaris CC; Widodo N; Shrestha BG; Kaur K; Ohtaka M; Yamasaki K; Kaul SC; Wadhwa R
Cancer Lett; 2007 Jul; 252(2):259-69. PubMed ID: 17306926
[TBL] [Abstract][Full Text] [Related]
2. Mortalin inhibitors sensitize K562 leukemia cells to complement-dependent cytotoxicity.
Pilzer D; Saar M; Koya K; Fishelson Z
Int J Cancer; 2010 Mar; 126(6):1428-35. PubMed ID: 19739077
[TBL] [Abstract][Full Text] [Related]
3. Relevance of mortalin to cancer cell stemness and cancer therapy.
Yun CO; Bhargava P; Na Y; Lee JS; Ryu J; Kaul SC; Wadhwa R
Sci Rep; 2017 Feb; 7():42016. PubMed ID: 28165047
[TBL] [Abstract][Full Text] [Related]
4. Rhodacyanine dye MKT-077 inhibits in vitro telomerase assay but has no detectable effects on telomerase activity in vivo.
Wadhwa R; Colgin L; Yaguchi T; Taira K; Reddel RR; Kaul SC
Cancer Res; 2002 Aug; 62(15):4434-8. PubMed ID: 12154051
[TBL] [Abstract][Full Text] [Related]
5. Mortalin inhibition in experimental Parkinson's disease.
Chiasserini D; Tozzi A; de Iure A; Tantucci M; Susta F; Orvietani PL; Koya K; Binaglia L; Calabresi P
Mov Disord; 2011 Aug; 26(9):1639-47. PubMed ID: 21542017
[TBL] [Abstract][Full Text] [Related]
6. Analogs of the Heat Shock Protein 70 Inhibitor MKT-077 Suppress Medullary Thyroid Carcinoma Cells.
Hong SK; Starenki D; Johnson OT; Gestwicki JE; Park JI
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162987
[TBL] [Abstract][Full Text] [Related]
7. Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function.
Wadhwa R; Sugihara T; Yoshida A; Nomura H; Reddel RR; Simpson R; Maruta H; Kaul SC
Cancer Res; 2000 Dec; 60(24):6818-21. PubMed ID: 11156371
[TBL] [Abstract][Full Text] [Related]
8. Treatment of ras-induced cancers by the F-actin-bundling drug MKT-077.
Tikoo A; Shakri R; Connolly L; Hirokawa Y; Shishido T; Bowers B; Ye LH; Kohama K; Simpson RJ; Maruta H
Cancer J; 2000; 6(3):162-8. PubMed ID: 10882332
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of the nucleotide-binding domain of mortalin, the mitochondrial Hsp70 chaperone.
Amick J; Schlanger SE; Wachnowsky C; Moseng MA; Emerson CC; Dare M; Luo WI; Ithychanda SS; Nix JC; Cowan JA; Page RC; Misra S
Protein Sci; 2014 Jun; 23(6):833-42. PubMed ID: 24687350
[TBL] [Abstract][Full Text] [Related]
10. Cellular mortality to immortalization: mortalin.
Wadhwa R; Kaul SC; Mitsui Y
Cell Struct Funct; 1994 Feb; 19(1):1-10. PubMed ID: 8069942
[TBL] [Abstract][Full Text] [Related]
11. Targeting of DNA Damage Signaling Pathway Induced Senescence and Reduced Migration of Cancer cells.
Gao R; Singh R; Kaul Z; Kaul SC; Wadhwa R
J Gerontol A Biol Sci Med Sci; 2015 Jun; 70(6):701-13. PubMed ID: 24747666
[TBL] [Abstract][Full Text] [Related]
12. Mortalin-based cytoplasmic sequestration of p53 in a nonmammalian cancer model.
Walker C; Böttger S; Low B
Am J Pathol; 2006 May; 168(5):1526-30. PubMed ID: 16651619
[TBL] [Abstract][Full Text] [Related]
13. Coupling astogenic aging in the colonial tunicate Botryllus schlosseri with the stress protein mortalin.
Ben-Hamo O; Rosner A; Rabinowitz C; Oren M; Rinkevich B
Dev Biol; 2018 Jan; 433(1):33-46. PubMed ID: 29128264
[TBL] [Abstract][Full Text] [Related]
14. Withanone binds to mortalin and abrogates mortalin-p53 complex: computational and experimental evidence.
Grover A; Priyandoko D; Gao R; Shandilya A; Widodo N; Bisaria VS; Kaul SC; Wadhwa R; Sundar D
Int J Biochem Cell Biol; 2012 Mar; 44(3):496-504. PubMed ID: 22155302
[TBL] [Abstract][Full Text] [Related]
15. MKT-077, a novel rhodacyanine dye in clinical trials, exhibits anticarcinoma activity in preclinical studies based on selective mitochondrial accumulation.
Koya K; Li Y; Wang H; Ukai T; Tatsuta N; Kawakami M; Shishido ; Chen LB
Cancer Res; 1996 Feb; 56(3):538-43. PubMed ID: 8564968
[TBL] [Abstract][Full Text] [Related]
16. SMR peptide antagonizes mortalin promoted release of extracellular vesicles and affects mortalin protection from complement-dependent cytotoxicity in breast cancer cells and leukemia cells.
Huang MB; Wu JY; Lillard J; Bond VC
Oncotarget; 2019 Sep; 10(52):5419-5438. PubMed ID: 31534628
[No Abstract] [Full Text] [Related]
17. Potentiation of the antiproliferative activity of MKT-077 by loperamide, diltiazem and tamoxifen.
Abdul M; Hoosein N
Oncol Rep; 2003; 10(6):2023-6. PubMed ID: 14534737
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and initial evaluation of YM-08, a blood-brain barrier permeable derivative of the heat shock protein 70 (Hsp70) inhibitor MKT-077, which reduces tau levels.
Miyata Y; Li X; Lee HF; Jinwal UK; Srinivasan SR; Seguin SP; Young ZT; Brodsky JL; Dickey CA; Sun D; Gestwicki JE
ACS Chem Neurosci; 2013 Jun; 4(6):930-9. PubMed ID: 23472668
[TBL] [Abstract][Full Text] [Related]
19. Mortalin: a potential candidate for biotechnology and biomedicine.
Wadhwa R; Taira K; Kaul SC
Histol Histopathol; 2002 Oct; 17(4):1173-7. PubMed ID: 12371145
[TBL] [Abstract][Full Text] [Related]
20. Induction of Senescence in Cancer Cells by a Novel Combination of Cucurbitacin B and Withanone: Molecular Mechanism and Therapeutic Potential.
Garg S; Huifu H; Kumari A; Sundar D; Kaul SC; Wadhwa R
J Gerontol A Biol Sci Med Sci; 2020 May; 75(6):1031-1041. PubMed ID: 31112603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
